

Appl. No. : 10/027,603  
Filed : December 19, 2001

#4  
As shown in Figure 21, four antibodies were found to neutralize EG-VEGF activity. These were antibodies 1C6.1H6.1D7, 2A3.1C5.1F3, 2A8.1H4.1E7 and 4H9.1A7.1H6. In particular, monoclonal antibody 4H9 was found to completely neutralize the activity of 10 nM EG-VEGF when added at a dose of 10 µg/ml or higher.

Please replace the table beginning on page 118, line 11 with the following replacement table:

5  
A

<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
DNA60621-1516	203091	August 4, 1998
1C6.1H6.1D7		
2A3.1C5.1F3		
2A8.1H4.1E7		
4H9.1A7.1H6		

**In the Claims:**

Please replace claim 1 with the following replacement claim:

A 6  
1. An antibody selected from the group consisting of anti-EG-VEGF monoclonal antibodies 1C6.1H6.1D7, 2A3.1C5.1F3, 2A8.1H4.1E7 and 4H9.1A7.1H6.

Please replace claim 2 with the following replacement claim:

A 7  
2. An antibody that binds essentially the same epitope of EG-VEGF bound by an antibody selected from the group consisting of anti-EG-VEGF monoclonal antibodies 1C6.1H6.1D7, 2A3.1C5.1F3, 2A8.1H4.1E7 and 4H9.1A7.1H6.

Please replace claim 15 with the following replacement claim:

A 8  
15. The composition of claim 14 wherein said antagonist is an anti-EG-VEGF antibody selected from the group consisting of monoclonal antibodies 1C6.1H6.1D7, 2A3.1C5.1F3, 2A8.1H4.1E7 and 4H9.1A7.1H6.

Please replace claim 16 with the following replacement claim: